Matrix Asset Advisors Inc. NY Sells 3,739 Shares of Amgen Inc. $AMGN

Matrix Asset Advisors Inc. NY lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 99,810 shares of the medical research company’s stock after selling 3,739 shares during the period. Amgen accounts for about 3.2% of Matrix Asset Advisors Inc. NY’s investment portfolio, making the stock its 11th biggest holding. Matrix Asset Advisors Inc. NY’s holdings in Amgen were worth $35,118,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Patriot Financial Group Insurance Agency LLC increased its position in Amgen by 301.9% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 7,838 shares of the medical research company’s stock worth $2,758,000 after buying an additional 5,888 shares in the last quarter. Lam Group Inc. bought a new position in shares of Amgen during the 1st quarter valued at approximately $163,000. Kenora Financial LLC increased its holdings in Amgen by 3.8% in the 1st quarter. Kenora Financial LLC now owns 9,035 shares of the medical research company’s stock worth $3,179,000 after acquiring an additional 333 shares in the last quarter. Caldwell Trust Co raised its stake in Amgen by 0.7% during the 1st quarter. Caldwell Trust Co now owns 31,631 shares of the medical research company’s stock worth $11,129,000 after acquiring an additional 233 shares during the period. Finally, Cornerstone Wealth Group LLC raised its stake in Amgen by 2.0% during the 1st quarter. Cornerstone Wealth Group LLC now owns 35,448 shares of the medical research company’s stock worth $12,225,000 after acquiring an additional 693 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on AMGN shares. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Jefferies Financial Group initiated coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $354.42.

Amgen Stock Up 0.1%

Shares of NASDAQ AMGN opened at $358.61 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The firm’s 50-day moving average price is $340.70 and its 200-day moving average price is $346.38. The stock has a market capitalization of $193.54 billion, a price-to-earnings ratio of 24.96, a P/E/G ratio of 3.60 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.